Human Cardiac Drug Response Prediction
Human Cardiac Drug Response Prediction
FilamenTech is a Boston-Belgrade deep-tech company building multiscale mechanistic simulation tools that turn experimental, preclinical, and clinical data into trustworthy predictions for cardiac and muscle disease drug development.
We combine physics-based modeling, high-performance computing, and domain expertise to reduce uncertainty and accelerate decisions across the drug development lifecycle.
To help drug developers reduce translational uncertainty by turning experimental and preclinical data into mechanistic predictions of human cardiac and muscle response.
A future where mechanism-aware prediction is standard for cardiac and muscle drug development.
Drug-development teams often generate high-quality experimental data but still face the same strategic uncertainty: what will this mechanism do in a human heart or muscle system? FilamenTech exists to help answer that question.
Five co-founders combining cardiac muscle science, computational platform engineering, product execution, commercial strategy, and capital markets experience.
Scientific architect of MUSICO and leader of FilamenTech’s translational modeling vision.
Leads operations, scientific program coordination, and client-facing execution.
Leads product execution and partner delivery, translating MUSICO into scalable workflows
Supports investor relations, family office outreach, and strategic capital partnerships. Draws on 30+ years in capital markets and investment management.
Leads software architecture, computational infrastructure, and platform implementation.
World-renowned experts guiding our science and strategy.
Muscle biochemistry, myosin motor function, and muscle regulation.
Bioengineering, muscle disease, contractile dysfunction, and computational modeling.
Cardiac muscle contraction, excitation–contraction coupling, and sarcomere mechanics.
Muscle biophysics, X-ray fiber diffraction, and synchrotron structural analysis.
Institutional affiliations are shown for identification only and do not imply endorsement of FilamenTech’s commercial services.
Our work is powered by two connected hubs-each bringing complementary strengths in research, engineering, and collaboration.
Close to leading research institutions and biotech partners. Focused on scientific innovation, partnerships, and customer engagement in North America.
Home to our core engineering and modeling teams. A vibrant tech and science community driving platform development and delivery.
Let’s explore how FilamenTech can help you unlock the value of your data and accelerate drug development with mechanistic, trustworthy insight.
Human cardiac prediction from data you already have.
FilamenTech develops multiscale mechanistic simulation workflows that help drug-development teams translate assay, tissue, animal, mutation, and structural data into human-relevant cardiac and muscle predictions.
Boston • Belgrade
Start with a focused pilot.
Evaluate mutation effects, drug responses, or translational hypotheses using mechanistic simulation workflows tailored to your program.
© 2026 FilamenTech. All rights reserved.
Created by Starter studio.
